Poster presentations association with serum IL-32 titer and clinical manifestation of patients with CD, and identify whether serum IL-32 test is helpful in the differential diagnosis between CD and intestinal tuberculosis (ITB). Methods: Serum samples from 48 patients with CD, 46 patients with ITB and 20 normal control were collected. Serum IL-32 gamma (most active isoform of IL-32) titer was measured by IL-32 gamma specific sandwich ELISA. Results: Serum IL-32 gamma titer in patients with CD was significantly elevated compared with patients with ITB and normal control (p < 0.01). Between patients with ITB and normal control, serum IL-32 gamma titers were not significantly different. In patients with CD, serum IL-32 gamma titer tended to be increased patients with clinical symptoms such as weight loss, abdominal pain and hematochezia, and patients with lesion involved small bowel and anorectal area (p > 0.05). In patients with CD, serum IL-32 gamma titer of normal CRP group was higher than elevated CRP group, but there was no significant difference between two groups (p = 0.068). The sensitivity, specificity, positive predictive value and negative predictive value of serum IL-32 gamma titier for diagnosis of CD were 64.6%, 73.9%, 45.7% and 54.3%, respectively. Conclusions: Serum IL-32gamma titer can represent CD activity and be helpful in the differential diagnosis between CD and ITB. However, prospective large studies are needed to verify the clinical usefulness of serum IL-32gamma titer in diagnosis and monitoring of CD.
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and 83/181 (47%) had IS and anti-TNF respectively at pCD diagnosis. Relapse rate was 51% within a mean time of 33 months. During follow-up 15% required a stoma. Predictive factors of relapse were perianal abscess (p < 0.0001, HR=4.4), fistula (p < 0.0001, HR=4.5) or surgical drainage at diagnosis (p < 0.0001, HR=4.5), young age at pCD diagnosis (28 versus 31 yo, p = 0.02), short time between CD and pCD diagnosis (5.7 versus 7 years, p = 0.01), IS (p = 0.04, HR=1.8) and anti-TNF (p = 0.01, HR=1.5) at pCD diagnosis. Anti-TNF during follow-up, time to introduce them and duration of anti-TNF treatment were not predictive of relapse. The young and old cohort had the same characteristics at pCD diagnosis except a higher use of IS (87% vs 48%, p < 0.0001) and anti-TNF (3% vs 68%, p < 0.0001) in the young cohort. Clinical outcome including the time to relapse, type of relapse, need for surgery and stoma was similar in both cohorts. Conclusions: In our cohort of pCD patients half of them had a perianal relapse over the time requiring surgery in more than 2/3 of them. At pCD diagnosis perianal abscess, fistula, surgical drainage, young age, treatment with IS or anti-TNF were associated with a higher risk of relapse. Although higher prescription of anti-TNF and IS in the last years new treatment strategies have not impacted the outcome of pCD.
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Clinical impact of magnifying chromoendoscopy on assessment of mucosal healing and prediction of disease relapse in quiescent ulcerative colitis Background: Mucosal healing (MH) has emerged as an important treatment goal in ulcerative colitis (UC). Several previous studies showed that achievement of mucosal healing is associated with medium-and long-term clinical outcome. However, there is no validated definition of MH. The aim of this study is to examine the usefulness of magnifying colonoscopy for evaluation of MH in UC.
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